New Food and Drug Administration-approved and emerging novel treatment options for acute myeloid leukemia Journal Article
| Authors: | Click, Z. R.; Seddon, A. N.; Bae, Y. R.; Fisher, J. D.; Ogunniyi, A. |
| Article Title: | New Food and Drug Administration-approved and emerging novel treatment options for acute myeloid leukemia |
| Abstract: | Advancements in the treatment of acute myeloid leukemia (AML) have been sparse during the past several decades, and the disease continues to have a poor prognosis. However, in 2017 alone, four new medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of AML reached the market. Midostaurin, liposomal cytarabine and daunorubicin, enasidenib, and gemtuzumab ogozamicin all showed benefit in respective clinical trials to gain approval for the treatment of AML in various patient populations. Additionally, many phase II and III clinical trials are currently ongoing to assess the safety and efficacy of other potential therapies for the treatment of AML. In this review, we summarize the results of the landmark clinical trials associated with the newly approved agents as well as the current ongoing clinical trials for the treatment of AML. A literature search was performed to retrieve data on agents currently being studied for use. Although the overall prognosis for patients with AML remains poor, the addition of the newly FDA-approved medications is a step in the right direction for a disease state that has proved difficult to treat. © 2018 Pharmacotherapy Publications, Inc. |
| Keywords: | cancer survival; treatment response; drug tolerability; fatigue; neutropenia; review; placebo; cancer combination chemotherapy; diarrhea; drug efficacy; drug safety; drug withdrawal; drug approval; cytarabine; ipilimumab; unindexed drug; cancer immunotherapy; drug eruption; infection; liver toxicity; anemia; bone marrow suppression; etoposide; bleeding; nausea; thrombocytopenia; qt prolongation; maintenance therapy; food and drug administration; protein tyrosine kinase inhibitor; dyspnea; febrile neutropenia; fever; drug antagonism; mitoxantrone; daunorubicin; patient compliance; colitis; pleura effusion; hyperbilirubinemia; idarubicin; ketoconazole; rifampicin; leukocytosis; lung infiltrate; azacitidine; drug induced disease; hematologic disease; induction chemotherapy; gemtuzumab ozogamicin; liver venoocclusive disease; hypertransaminasemia; midostaurin; dna methyltransferase inhibitor; acute myeloid leukemia; gemtuzumab; cancer prognosis; decitabine; consolidation chemotherapy; quizartinib; nivolumab; human; pembrolizumab; venetoclax; atezolizumab; crenolanib; cytarabine plus daunorubicin; gilteritinib; guadecitabine; avelumab; enasidenib; antineoplastic monoclonal antibody; ivosidenib; aml pipeline; vyxeos; isocitrate dehydrogenase inhibitor; vorasidenib; isocitrate dehydrogenase differentiation syndrome |
| Journal Title: | Pharmacotherapy |
| Volume: | 38 |
| Issue: | 11 |
| ISSN: | 0277-0008 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2018-11-01 |
| Start Page: | 1143 |
| End Page: | 1154 |
| Language: | English |
| DOI: | 10.1002/phar.2180 |
| PUBMED: | 30220082 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 3 December 2018 -- Source: Scopus |
